The FDA and its oncology advisory committee raised lots of questions on whether Amgen’s confirmatory trial is enough to convert an accelerated approval to a full approval for Lumakras (sotorasib) to treat those with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
And the adcomm voted…
Click here to view original post
